Immorta Bio Reports | SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy

SenoVax has previously been demonstrated to reduce lung cancer growth1, which was the subject of the Company's IND #307452. It has also been shown to accelerate recovery of blood cell production after chemotherapy notes Immorta Bio.

Continue ReadingImmorta Bio Reports | SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy